Cyduct Diagnostics Inc
CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It a… Read more
Cyduct Diagnostics Inc (CYDX) - Net Assets
Latest net assets as of June 2025: $-2.81 Million USD
Based on the latest financial reports, Cyduct Diagnostics Inc (CYDX) has net assets worth $-2.81 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.68K) and total liabilities ($2.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.81 Million |
| % of Total Assets | -7454.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cyduct Diagnostics Inc - Net Assets Trend (2016–2025)
This chart illustrates how Cyduct Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cyduct Diagnostics Inc (2016–2025)
The table below shows the annual net assets of Cyduct Diagnostics Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-2.81 Million | -17.27% |
| 2024-06-30 | $-2.40 Million | -18.37% |
| 2023-06-30 | $-2.02 Million | -30.49% |
| 2022-06-30 | $-1.55 Million | -37.20% |
| 2021-06-30 | $-1.13 Million | -50.17% |
| 2020-06-30 | $-752.64K | +42.75% |
| 2019-06-30 | $-1.31 Million | +58.65% |
| 2018-06-30 | $-3.18 Million | -17.46% |
| 2017-06-30 | $-2.71 Million | -86.34% |
| 2016-06-30 | $-1.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cyduct Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 178929400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.14K | % |
| Other Components | $11.74 Million | % |
| Total Equity | $-2.81 Million | 100.00% |
Cyduct Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Cyduct Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INEP3F
SA:INEP3F
|
$1.95K |
|
Real American Capita
PINK:RLAB
|
$1.95K |
|
The Container Store Group, Inc.
PINK:TCSG
|
$1.95K |
|
Access Engineering PLC
CM:AELN0000
|
$1.95K |
|
RNEW3F
SA:RNEW3F
|
$1.94K |
|
CONSORCIO ARA (4GJ.SG)
STU:4GJ
|
$1.94K |
|
METALLURGICAL -H-
MU:6MT
|
$1.94K |
|
Kingland Property Corporation Ltd.
TWO:6264
|
$1.94K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyduct Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,395,060 to -2,808,674, a change of -413,614.
- Net loss of 413,614 reduced equity.
- Other factors decreased equity by 0.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-413.61K | -14.73% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cyduct Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | $-7.30 | $0.20 | x |
| 2017-06-30 | $-9.74 | $0.20 | x |
| 2018-06-30 | $-6.74 | $0.20 | x |
| 2019-06-30 | $-2.15 | $0.20 | x |
| 2020-06-30 | $-0.26 | $0.20 | x |
| 2021-06-30 | $-0.23 | $0.20 | x |
| 2022-06-30 | $-0.30 | $0.20 | x |
| 2023-06-30 | $-0.39 | $0.20 | x |
| 2024-06-30 | $-0.46 | $0.20 | x |
| 2025-06-30 | $-0.54 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyduct Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -585.13%
- • Asset Turnover: 1.88x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -1370.17% | 0.22x | 0.00x | $-3.50 Million |
| 2017 | 0.00% | -562.56% | 0.22x | 0.00x | $-1.21 Million |
| 2018 | 0.00% | -265.92% | 1.49x | 0.00x | $-299.51K |
| 2019 | 0.00% | 1039.25% | 1.46x | 0.00x | $2.05 Million |
| 2020 | 0.00% | 287.53% | 1.90x | 0.00x | $634.32K |
| 2021 | 0.00% | -231.33% | 2.25x | 0.00x | $-259.01K |
| 2022 | 0.00% | -447.08% | 0.32x | 0.00x | $-265.42K |
| 2023 | 0.00% | -396.13% | 1.48x | 0.00x | $-270.40K |
| 2024 | 0.00% | -494.81% | 1.54x | 0.00x | $-178.53K |
| 2025 | 0.00% | -585.13% | 1.88x | 0.00x | $-132.75K |
Industry Comparison
This section compares Cyduct Diagnostics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyduct Diagnostics Inc (CYDX) | $-2.81 Million | 0.00% | N/A | $1.95K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |